For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250306:nRSF5439Za&default-theme=true
RNS Number : 5439Z Reckitt Benckiser Group PLC 06 March 2025
6(th) March 2025
RECKITT BENCKISER GROUP PLC
Appointment of Joint Corporate Broker
Reckitt Benckiser Group plc today announces the appointment of Barclays Bank
plc as its Joint Corporate Broker with immediate effect, to act alongside J.P.
Morgan Securities plc and Morgan Stanley & Co. International plc.
For further information please contact:
Investors:
Nick Ashworth
+44 (0) 7408 812350
Media:
Patty O'Hayer
+44
(0) 7825 755688
About Reckitt:
Reckitt* exists to protect, heal and nurture in the relentless pursuit of a
cleaner, healthier world. We believe that access to the highest-quality
hygiene, wellness and nourishment is a right, not a privilege.
Reckitt is the company behind some of the world's most recognisable and
trusted consumer brands in hygiene, health and nutrition, including Air Wick,
Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol,
Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and
more.
Every day, more than 20 million Reckitt products are bought globally. We
always put consumers and people first, seek out new opportunities, strive for
excellence in all that we do and build shared success with all our partners.
We aim to do the right thing, always.
We are a diverse global team of c. 40,000 colleagues. We draw on our
collective energy to meet our ambitions of purpose-led brands, a healthier
planet and a fairer society. Find out more, or get in touch with us
at www.reckitt.com (http://www.reckitt.com/)
* Reckitt is the trading name of the Reckitt Benckiser group of companies
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END APPKZGGFRKVGKZM